FDA Inspection 593230 — Glaxosmithkline
The FDA completed an inspection of Glaxosmithkline on Jun 12, 2009 in Marly le Roi. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Jun 12, 2009
- Fiscal Year
- 2009
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Marly le Roi (France)
Additional details
Postmarket Adverse Drug Experience (PADE)